Taysha gene therapies to host first annual stockholder meeting

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced its first annual stockholder meeting will be held june 17, 2021 at 10 am et via webcast. the webcast for this meeting will be available in the “events & presentations” s
TSHA Ratings Summary
TSHA Quant Ranking